Theriva Biologics, Inc. has announced a significant corporate action that could reshape its market presence. The company’s Board of Directors approved a 1-for-30 reverse stock split of its common stock. This decision, communicated through a press release on November 20, 2026, is set to take effect at 11:59 p.m. on December 1, 2026. The reverse stock split is crucial for ensuring compliance with the NYSE American's share price requirements.
As a result of the reverse stock split, the number of outstanding shares will decrease from approximately 45.9 million to about 1.53 million. The authorized shares will also be reduced proportionally, from 350 million to around 11.67 million. This strategic move aims to enhance the per-share value of the stock, which is essential for maintaining its listing on the NYSE American.
Theriva Biologics, Inc. operates in the pharmaceutical preparations sector, focusing on developing therapeutics for cancer and related diseases. The company is noted for its innovative oncolytic adenovirus platform, which targets tumor cells while enhancing the effectiveness of co-administered therapies. The announcement of the reverse stock split comes as the company seeks to bolster its market position amid ongoing challenges in the pharmaceutical industry.
The filing indicates that the reverse stock split was authorized on November 13, 2026, under the laws of Nevada, where the company is incorporated. The Board of Directors has the authority to implement this split without needing shareholder approval, provided the number of authorized and outstanding shares is proportionally adjusted.
Following the split, stockholders will not receive fractional shares. Instead, those entitled to a fractional share will automatically receive an additional share to round up to the nearest whole number. This adjustment is designed to simplify the transition for investors.
Theriva's transfer agent, Equiniti Trust Company, will facilitate the exchange of old stock certificates for new ones, although shareholders holding shares in brokerage accounts will not need to take any action. The company’s common stock will continue to trade under the ticker symbol “TOVX” but will do so under a new CUSIP number.
This reverse stock split reflects a broader trend in the pharmaceutical preparations industry, where companies are increasingly taking measures to maintain compliance with exchange listing standards. As market conditions fluctuate, firms may consider similar strategies to enhance their stock value and investor appeal.
Looking ahead, Theriva Biologics has not specified any further actions or filings following this announcement. The company is expected to continue its focus on advancing its clinical-stage candidates, including its lead product, VCN-01, which is designed to improve treatment outcomes for cancer patients.
For more information on Theriva Biologics, visit their website at www.therivabio.com.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




